^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Adenocarcinoma
    Regimen:NALIRIFOX
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    06/19/2023
    Excerpt:
    Pancreatic Adenocarcinoma….Locally Advanced Disease (First-Line Therapy)….Good PS 0-1….Other Recommended Regimens...Liposomal irinotecan + 5-FU + leucovorin + oxaliplatin (NALIRIFOX).
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet
    Title:

    NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

    Published date:
    09/11/2023
    Excerpt:
    Median overall survival was 11·1 months (95% CI 10·0–12·1) with NALIRIFOX versus 9·2 months (8·3–10·6) with nab-paclitaxel–gemcitabine (hazard ratio 0·83; 95% CI 0·70–0·99; p=0·036)….Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.
    DOI:
    https://doi.org/10.1016/S0140-6736(23)01366-1
    Trial ID:
    NAPOLI-3